Polypeptide Group AG

Polypeptide Group AG is a leading independent manufacturer specializing in peptide- and oligonucleotide-based active pharmaceutical ingredients (APIs). Operating as a Contract Development & Manufacturing Organization (CDMO), the company supports pharmaceutical and biotechnology firms with customized development and large-scale production of proprietary and generic peptide APIs. Since its founding in 1952, Polypeptide Group AG has cultivated deep expertise in GMP-quality manufacturing, with a global footprint that includes facilities in Europe, the United States, and India. The company’s offerings are integral to therapies addressing metabolic diseases, cancer, cardiovascular, and neurological disorders, among others. Polypeptide Group AG’s focus on innovation, operational excellence, and collaborative partnership enables it to serve clients from early drug research through to commercial product launch, underpinning key advances in modern medicine and contributing to the health of millions of patients worldwide. Its position in a rapidly growing sector underscores its importance to both the pharmaceutical supply chain and advancements in peptide-based therapeutics.